Compare STRT & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRT | ABEO |
|---|---|---|
| Founded | 1908 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 318.7M | 281.0M |
| IPO Year | 1995 | 1980 |
| Metric | STRT | ABEO |
|---|---|---|
| Price | $75.51 | $5.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $18.20 |
| AVG Volume (30 Days) | 56.5K | ★ 1.1M |
| Earning Date | 02-05-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.55 | N/A |
| EPS | ★ 5.73 | 1.29 |
| Revenue | ★ $578,413,000.00 | $400,000.00 |
| Revenue This Year | $4.15 | N/A |
| Revenue Next Year | $4.12 | $1,589.77 |
| P/E Ratio | $13.13 | ★ $4.06 |
| Revenue Growth | ★ 6.83 | N/A |
| 52 Week Low | $31.57 | $3.93 |
| 52 Week High | $83.26 | $7.54 |
| Indicator | STRT | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 45.95 | 49.25 |
| Support Level | $72.01 | $5.07 |
| Resistance Level | $77.50 | $5.31 |
| Average True Range (ATR) | 2.71 | 0.21 |
| MACD | -0.87 | -0.03 |
| Stochastic Oscillator | 30.04 | 41.89 |
Strattec Security Corp designs develops, manufactures, and markets mechanical locks, electronically enhanced locks, and keys. It also produces ignition lock housings; and access control products, including latches, power sliding door systems, and door handles. Strattec ships products to customer locations in the United States, Canada, Mexico, Europe, South America, Korea, and China, and provides full-service aftermarket support. Strattec also supplies products for the heavy truck and recreational vehicle markets, as well as precision, die castings.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.